AstraZeneca: Enhertu Phase 2 Trial Meets Primary Endpoint
27 Gennaio 2020 - 8:58AM
Dow Jones News
By Anthony O. Goriainoff
AstraZeneca PLC (AZN.LN) said on Monday that the Phase 2 trial
for Enhertu, its gastric cancer drug, met its primary endpoint.
The U.K. pharmaceutical company said the trial met the primary
endpoint of objective response rate and key secondary endpoint of
overall survival in patients with previously treated HER2-positive
metastatic gastric cancer compared to an investigator's choice of
chemotherapy.
"Given the previous results seen in our HER2-positive
development program and now in HER2-positive metastatic gastric
cancer, we believe this antibody drug conjugate has the potential
to redefine the treatment of patients with HER2-expressing
cancers," the company said.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
January 27, 2020 02:43 ET (07:43 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024
